Author | Lightnews

Reposted by Mads Israelsen

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · Sep 11

New research - Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study

www.thelancet.com/journals/lan...

#LiverSky #MedSky @aleksanderkrag.bsky.social @israelsenm.bsky.social

1 5

Mads Israelsen @israelsenm.bsky.social · Sep 11

How should we use PEth in SLD care? 🩸🍺

Our study in @lancetgastrohep.bsky.social (n≈3,000) shows:
🔍 39% of MASLD → MetALD/ALD with PEth
⨻ Triangulating self-report + AUDIT-C + PEth = better classification
⚖️ But 40% get no added value → use selectively

www.sciencedirect.com/science/arti...

Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study

Phosphatidylethanol is a direct biomarker of alcohol consumption within the past 1–4 weeks, making it a potential tool in the subclassification of pat…

www.sciencedirect.com

1 4

Reposted by Mads Israelsen

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · Jul 16

New Review - Screening for advanced steatotic liver disease

www.thelancet.com/journals/lan...

#LiverSky #MedSky @aleksanderkrag.bsky.social

Screening for advanced steatotic liver disease

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...

www.thelancet.com

4 4

Reposted by Mads Israelsen

JHEP Reports @jhep-reports.bsky.social · Jun 24

🎉Our new Impact Factor is 7.5!

We are firmly among the top journals in hepatology👏

Thank you to our authors, reviewers & readers!🙏

#LiverSky
@easlnews.bsky.social

2 5

Reposted by Mads Israelsen

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · Jun 6

New Editorial — Alcohol and health: time for Europe to sober up

www.thelancet.com/journals/lan...

#alcohol #liversky #medsky

1 7 9

Reposted by Mads Israelsen

Journal of Hepatology @jhepatology.bsky.social · Jun 18

📢Our new Impact Factor is 33.0🎉

🥇Ranking number 1 in the Hepatology field🥇

👏Thanks to the Editorial Team, untiring peer reviewers & very innovative authors❕

#LiverSky
@easlnews.bsky.social

3 11

Reposted by Mads Israelsen

A-TANGO Project @a-tango.bsky.social · May 12

✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.

🗓️ What a fun #workshop at #EASLCongress 2025

1 3 7

Reposted by Mads Israelsen

MICROB-PREDICT @microb-predict.bsky.social · May 10

🧪 Mads Israelsen (Odense Universitetshospital – Svendborg Sygehus) leads together with Alberto Zanetto the YI #Workshop on How to prepare a #Clinical #Practice #Guideline in Hepatology, offering valuable insights for young investigators.

📅 Presented at the #EASLCongress | #EASL2025

3 6

Reposted by Mads Israelsen

MICROB-PREDICT @microb-predict.bsky.social · May 10

One last time #LIVE from the #EASLStudio: Tot Ziens Amsterdam, Hola Barcelona! 👋

As #EASL2025 draws to a close, Debbie Shawcross and Aleksander Krag reflect on the highlights from Amsterdam and set the stage for #EASL2026 in Barcelona.

Thank you for an inspiring #EASLCongress - see you next year!

1 3 5

Reposted by Mads Israelsen

MICROB-PREDICT @microb-predict.bsky.social · May 8

🤩 Full house at General Session 1 today 🥳

Abstract Session “General #Hepatology”, chaired by Aleksander Krag from Odense University Hospital in Denmark 🇩🇰, featuring a broad range of cutting-edge #LiverResearch 🔬.

📅 Presented at #EASLCongress | #EASL2025

🕥 10:30 – 12:30 h

@easlnews.bsky.social

4 11

Reposted by Mads Israelsen

MICROB-PREDICT @microb-predict.bsky.social · May 8

📚 Learning from the best at the EASL Congress: Maja Thiele (OUH) discusses Alcohol-related liver disease as part of The JHEP Reports Symposium: Keys to get your manuscript accepted. 💡
#EASL2025

3 5

Reposted by Mads Israelsen

MICROB-PREDICT @microb-predict.bsky.social · May 8

🐭 Blockage of microfibrillar-associated protein 4 (MFAP4) decreases liver fibrosis in two murine models of steatotic liver disease

#POSTER THU-058-YI by Maximilian Brol (UM) presents preclinical data showing that blocking MFAP4 reduces #liver #fibrosis in two murine models.

#EASL2025

1 4 7

Reposted by Mads Israelsen

NEJM.org @nejm.org · Apr 30

In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

#MedSky #EndoSky #GastroSky

The figure shows the percentage of patients with fibrosis stage 2 or 3 who had resolution of steatohepatitis with no worsening of liver fibrosis (Panel A) and reduction in liver fibrosis with no worsening of steatohepatitis (Panel B) after 72 weeks, with the estimated difference expressed in percentage points.

9 20

Reposted by Mads Israelsen

Hannes Hagström @liverepi.bsky.social · Apr 13

🚨New paper from us in Journal of Hepatology - Using PEth values on >50,000 persons to predict outcomes. www.sciencedirect.com/science/arti...

Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes

Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion …

www.sciencedirect.com

1 3 11

Mads Israelsen @israelsenm.bsky.social · Apr 10

@aleksanderkrag.bsky.social

Reposted by Mads Israelsen

Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Mar 31

APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol"

www.nature.com/articles/s41...

#Liversky

Fig. 4: The bidirectional linking of factors that predispose to steatotic liver disease.

2 4

Reposted by Mads Israelsen

Mads Israelsen @israelsenm.bsky.social · Apr 8

@aga-cgh.bsky.social
@majathiele.bsky.social
@aleksanderkrag.bsky.social

#Thorhauge

1

Mads Israelsen @israelsenm.bsky.social · Apr 8

@aga-cgh.bsky.social
@majathiele.bsky.social
@aleksanderkrag.bsky.social

#Thorhauge

1

Mads Israelsen @israelsenm.bsky.social · Apr 8

Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️

Over 60% with MetALD/ALD and 38% with MASLD change subclass.

This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐

Link: www.cghjournal.org/article/S154...

Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments

Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...

www.cghjournal.org

1 1 8

Reposted by Mads Israelsen

Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Mar 31

#liversky #gastrosky #oncsky

Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Mar 31

Our APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more!

www.nature.com/nrgastro/vol...

Steatotic liver disease burden paradox, inspired by the Perspective on p281.

1 7

Mads Israelsen @israelsenm.bsky.social · Apr 1

MASLD vs MetALD/ALD is often reduced to ‘alcohol or not’.

But alcohol use is not binary—and SLD is a dynamic spectrum where alcohol plays a significant role across phenotypes.

Time to rethink the simplistic divide 🧐

@aleksanderkrag.bsky.social
@natrevgastrohep.bsky.social

5

Reposted by Mads Israelsen

EASL @easlnews.bsky.social · Mar 17

Have you secured your spot for #EASLCongress 2025 on 7-10 May?

🌍Join us in Amsterdam or online to transform liver care worldwide! easlcongress.eu/2025-registr...
📜The deadline to submit your late-breaker abstract is TODAY, 17 March! easlcongress.eu/2025-abstrac...

2 5

Reposted by Mads Israelsen

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · Mar 12

New Review - Neurath, Artis, Becker - The intestinal barrier: a pivotal role in health, inflammation, and cancer

www.thelancet.com/journals/lan...

#GastroSky #MedSky

4 7

Reposted by Mads Israelsen

Elliot Tapper @ebtapper.bsky.social · Mar 9

AASLD is here

@aasldnews.bsky.social
@aasldfoundation.bsky.social

#liversky

Elliot Tapper @ebtapper.bsky.social · Nov 15

We are on our second starter pack for GI / Hepatology
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR

#medsky #GIsky #LiverSky

5 10

Reposted by Mads Israelsen

Bork Group at EMBL Heidelberg @borklab.bsky.social · Feb 26

We're once again hosting the Human #Microbiome conference at @embl.org, organized by Ami Bhatt, Nicola Segata, Mani Arumugam and Peer Bork! We always have a great lineup of speakers, so register now and think about an abstract to submit (abstract submission deadline in June)

EMBL Events @events.embl.org · Feb 26

📣 Explore cutting-edge breakthroughs in microbiome research, from methodological innovations to integrative approaches and personalised therapeutics. Join #EESMicrobiome!🦠

📅 16 – 19 Sep 2025
📍 EMBL Heidelberg and Virtual
📥 Submit your abstract by 24 June

➡️ https://s.embl.org/ees25-08-bl

11 18